Graham tells FDA to pull 'toxic' Ketek from market

Share this article:
FDA drug safety expert, whistleblower Dr. David Graham, has called on FDA officials to pull from the market Sanofi-Aventis' controversial antibiotic Ketek, saying it is as toxic, "if not more so," as three other drugs [Rezulin, Trovan and Duract] pulled from the market for liver problems. The FDA has already revised Ketek's labeling.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.